首页> 美国卫生研究院文献>Journal of Korean Medical Science >Experience of International Air Transportation and Subsequent Lung Transplant in a Patient with COVID-19-associated Acute Respiratory Distress Syndrome: a Case Report
【2h】

Experience of International Air Transportation and Subsequent Lung Transplant in a Patient with COVID-19-associated Acute Respiratory Distress Syndrome: a Case Report

机译:患有Covid-19相关急性呼吸窘迫综合征的患者中国际空运和随后的肺移植的经验:案例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We report an inspiring case of a 55-year-old Korean female diagnosed with coronavirus disease 2019 (COVID-19)-associated acute respiratory distress syndrome (ARDS) in Mexico. The patient was assessed for lung transplant as a salvage therapy for treatment-refractory ARDS following no signs of clinical improvement for > 7 weeks, despite best treatment. The patient was transported from Mexico to Korea by air ambulance under venovenous extracorporeal membrane oxygenation (ECMO) support. She was successfully bridged to lung transplant on day 88, 49 days after the initiation of ECMO support. ECMO was successfully weaned at the end of operation, and no bleeding or primary graft dysfunction was observed within the first 72 hours. The patient was liberated from mechanical ventilation on postoperative day 9 and transferred to the general ward 5 days later. Despite the high doses of immunosuppressants, there was no evidence of viral reactivation after transplant. At 3 months post-transplantation, she was discharged to home without complication. Our experience suggests that successful lung transplant for COVID-19-associated ARDS is feasible even in a patient with prolonged pre-transplant ECMO support. Lung transplant may be considered a salvage therapy for COVID-19-associated ARDS that does not respond to conventional treatments.
机译:我们举行了墨西哥冠心病症(Covid-19)诊断为冠状病毒疾病的55岁韩国女性的令人兴奋的案例。患者被评估为肺移植,作为治疗 - 难治性ARDS的救生疗法,仍然在> 7周内临床改善的迹象,尽管最好的治疗。通过空气救护车在静脉内膜氧合(ECMO)支持下,患者从墨西哥运输到韩国。她在2008年第88天成功地桥接到了ECMO支持后49天的肺部移植。 ECMO在操作结束时成功断奶,并且在前72小时内没有观察到出血或初级移植功能障碍。患者从术后第9天的机械通风中解放,并在5天后转移到普通病房。尽管有高剂量的免疫抑制剂,但移植后没有病毒再活化的证据。在移植后3个月,她在没有并发症的情况下放出回家。我们的经验表明,即使在具有长期预移植ECMO支持的患者中,Covid-19相关ARD的成功肺移植也是可行的。肺移植可能被认为是对Covid-19相关的ARDS的救助疗法,其不响应常规治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号